Century Therapeutics Ownership
| IPSC Stock | USD 0.56 0.01 1.82% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 78.6 M | Current Value 86.1 M | Avarage Shares Outstanding 59.4 M | Quarterly Volatility 13.4 M |
Century Stock Ownership Analysis
About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.2. Some equities with similar Price to Book (P/B) outperform the market in the long run. Century Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.26. The entity recorded a loss per share of 0.27. The firm had not issued any dividends in recent years. Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. Century Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 170 people. To learn more about Century Therapeutics call PharmD MBA at 267 817 5790 or check out https://www.centurytx.com.Besides selling stocks to institutional investors, Century Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Century Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Century Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Century Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 25.0% of Century Therapeutics are currently held by insiders. Unlike Century Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Century Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Century Therapeutics' insider trades
Century Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Century Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Century Therapeutics backward and forwards among themselves. Century Therapeutics' institutional investor refers to the entity that pools money to purchase Century Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-03-31 | 846.2 K | Superstring Capital Management Lp | 2025-03-31 | 463 K | Northern Trust Corp | 2025-03-31 | 289.6 K | Acadian Asset Management Llc | 2025-03-31 | 284.2 K | Charles Schwab Investment Management Inc | 2025-03-31 | 270.8 K | Baker Bros Advisors Lp | 2025-03-31 | 241.7 K | Goldman Sachs Group Inc | 2025-03-31 | 179.6 K | Nuveen Asset Management, Llc | 2024-12-31 | 157.3 K | Nuveen, Llc | 2025-03-31 | 157.3 K | Bain Capital Life Sciences Investors, Llc | 2025-03-31 | 5.4 M | Casdin Capital, Llc | 2025-03-31 | 3.2 M |
Century Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Century Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Century Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Century Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Century Therapeutics Outstanding Bonds
Century Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Century Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Century bonds can be classified according to their maturity, which is the date when Century Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US156700BD72 Corp BondUS156700BD72 | View | |
| CenturyLink 765 percent Corp BondUS156700AT34 | View | |
| CENTURYLINK INC 76 Corp BondUS156700AM80 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share 1.358 | Quarterly Revenue Growth 126.677 | Return On Assets (0.06) | Return On Equity |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.